Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by 2seventy bio, Inc.
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 07, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
August 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
June 26, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Participate in Upcoming Investor Conferences
May 23, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 08, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
May 03, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
April 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
March 20, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
March 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
March 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Participate in Upcoming Investor Conferences
February 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces New Strategic Path Forward
January 30, 2024
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
December 11, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
December 06, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 14, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
November 10, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
September 12, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
September 06, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 14, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
August 08, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
June 14, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Participate in Upcoming Investor Conference
June 07, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
May 17, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
May 11, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 03, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
April 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
March 16, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
March 08, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
March 03, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
February 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
Tickers
TSVT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.